Role of Tissue Plasminogen Activator in Acute Ischemic Stroke

Abstract

Spanish

French

Objective:

To evaluate the literature regarding the use of intravenous tissue plasminogen activator (tPA) in the treatment of acute ischemic stroke, focusing on the appropriate usage criteria and administration time window.

Data Sources:

A PubMed and MEDLINE search was performed (1990-November 2010) using the key words alteplase, tissue plasminogen activator, thrombolytic, ischemic stroke, and cerebrovascular accident.

Study Selection and Data Extraction:

Clinical trials published in English were evaluated and relevant primary literature evaluating the use of tPA in acute ischemic stroke was included.

Data Synthesis:

The NINDS (National Institute of Neurological Disorders and Stroke) trial revealed clinical efficacy of tPA in the treatment of acute ischemic stroke when administered within 3 hours of stroke symptom onset and served as the foundation for the American Heart Association/American Stroke Association (AHA/ASA) acute ischemic stroke guideline recommendations. The ECASS (European Cooperative Acute Stroke Study) I, ECASS II, and ATLANTIS (Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke), part A and B, trials each assessed the efficacy of tPA when administered beyond 3 hours of ischemic stroke onset, but the results of each trial did not support its use beyond 3 hours. The ECASS III trial showed clinical efficacy of tPA when administered up to 4.5 hours. The SITS-MOST (Safe Implementation of Thrombolysis in Stroke-Monitoring Study) and SITS-ISTR (Safe Implementation of Thrombolysis in Stroke International Stroke Thrombolysis Register) registries evaluated the safety and efficacy of tPA at both 3 and 4.5 hours and showed promising results. In 2009, the AHA/ASA stroke guidelines were updated to support the use of tPA in select patients up to 4.5 hours after symptom onset.

Conclusions:

tPA is effective when administered up to 4.5 hours after ischemic stroke symptom onset in select patients. However, timely administration remains paramount to achievement of optimal therapeutic outcomes.

Keywords

alteplase cerebrovascular accident ischemic stroke thrombolytic tissue plasminogen activator

Get full access to this article

View all access options for this article.

References

Lloyd-Jones

, Adams

, Carnethon

. Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 119:e21–181.

Sacco

, Adams

, Albers

. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. A statement for health care professionals from the American Heart Association/American Stroke Association Council on Stroke. Stroke 2006; 37:577–617.

Goldstein

, Appel

, Brass

. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke 2006; 37:1583–633.

Adams

, Del Zoppo

, Alberts

. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association. Stroke 2007; 38:1655–711.

Albers

, Amarenco

, Easton

. Antithrombotic and thrombolytic therapy. Chest 2008; 133:630S–69S.

Product information. Activase (alteplase). San Francisco, CA: Genentech, December 2005.

The National Institute of Neurological Disorders and Stroke rt-PA Stroke study group (NINDS). Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333:1581–7.

Hacke

, Kaste

, Fieschi

. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274:1017–25.

Hacke

, Kaste

, Fieschi

. Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Lancet 1998; 352:1245–51.

10.

Clark

, Albers

, Madden

, Hamilton

. The rtPA (alteplase) 0-to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Stroke 2000; 31:811–6.

11.

Clark

, Wissman

, Alber

, Jhamandas

, Madden

, Hamilton

. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset—the ATLANTIS study: a randomized controlled trial. JAMA 1999; 282:2019–26.

12.

Hacke

, Kaste

, Bluhmki

. Thrombolysis with alteplase 3 to 45 hours after acute ischemic stroke. N Engl J Med 2008; 359:1317–29.

13.

del Zoppo

, Saver

, Jauch

, Adams

Jr . Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator. A science advisory from the American Heart Association/American Stroke Association. Stroke 2009; 40:2945–8.

14.

Lees

, Bluhmki

, von Kummer

. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375:1695–703.

15.

Brott

, Haley

Jr , Levy

. Urgent therapy for stroke. I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992; 23:632–40.

16.

Haley

Jr , Levy

, Brott

. Urgent therapy for stroke. II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 1992; 23:641–5.

17.

Wahlgren

, Ahmed

, Davalos

. Thrombolysis with alteplase for acute ischemic stroke in the safe implementation of thrombolysis in stroke-monitoring study (SITS-MOST): an observational study. Lancet 2007; 369:275–82.

18.

Wahlgren

, Ahmed

, Davalos

. Thrombolysis with alteplase 3-4.5 hours after acute ischemic stroke (SITS-ISTR): an observational study. Lancet 2008; 372:1303–09.

19.

Ahmed

, Wahlgren

, Grond

. Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurology 2010; 9:866–874.